title: Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.
abstract: We investigated the inhibitory interaction potential of 22 currently marketed antituberculosis (TB) drugs on organic anion-transporting polypeptide 1B1 (OATP1B1)-, OATP2B1-, and OATP1B3-mediated uptake using in vitro Xenopus oocytes and HEK cells. Rifabutin, ethambutol, amoxicillin, linezolid, p-amino salicylic acid, and rifapentine exhibited mild to moderate inhibitory effects on OATP-mediated uptake of estrone-3 sulfate, estradiol 17β-d-glucuronide, and rosuvastatin. The 50% inhibitory concentration (IC50) values of rifabutin, amoxicillin, ethambutol, p-amino salicylic acid, and linezolid were 35.4, 36.2, 57.6, 72.6, and 65.9 μM, respectively, for uptake mediated by organic anionic transporter polypeptide 1B1 (OATP1B1) and 28.8, 28.9, 53.9, 31.5, and 61.0 μM, respectively, for uptake mediated by organic anionic transporter polypeptide 1B3 (OATP1B3). Streptomycin and linezolid showed greater inhibition of organic anionic transporter polypeptide 2B1 (OATP2B1)-mediated uptake, with IC50 values of 33.2 and 35.6 μM, respectively, along with mild inhibition of other drugs. Furthermore, rifabutin, amoxicillin, and rifapentine significantly inhibited OATP1B1-mediated rosuvastatin uptake, with IC50 values of 12.3, 13.0, and 11.0 μM, respectively, which showed a similar profile to estrone-3 sulfate uptake. The calculated R values ([I]u inlet,max/Ki, where [I]u inlet,max represents the maximum estimated inhibitor concentration inlet to the liver and Ki is the inhibition constant) as the drug-drug interaction (DDI) indexes of PAS, ethambutol, and amoxicillin were 26.1, 6.5, and 4.3 for OATP1B1 and 52.0, 8.0, and 4.6 for OATP1B3, and those for streptomycin, amikacin, and linezolid were 5.0, 4.2, and 4.4 for OATP2B1, respectively, suggesting a higher possibility of in vivo DDIs. This study is the first comprehensive report to show the novel inhibitory potential of 22 marketed anti-TB drugs on OATP-mediated uptake, providing evidence for future in vivo clinical DDI studies.
authors.affiliation: Department of Pharmacology, PharmacoGenomics Research Center (PGRC), Inje University College of Medicine, Busan, Republic of Korea.
authors.forename: M Masud
authors.initials: MM
authors.lastname: Parvez
authors.affiliation: Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Republic of Korea.
authors.forename: Jin Ah
authors.initials: JA
authors.lastname: Jung
authors.affiliation: Department of Pharmacology, PharmacoGenomics Research Center (PGRC), Inje University College of Medicine, Busan, Republic of Korea.
authors.forename: Ho Jung
authors.initials: HJ
authors.lastname: Shin
authors.affiliation: Department of Pharmacology, PharmacoGenomics Research Center (PGRC), Inje University College of Medicine, Busan, Republic of Korea.
authors.forename: Dong Hyun
authors.identifier: 0000-0001-9807-4064
authors.initials: DH
authors.lastname: Kim
authors.affiliation: Department of Pharmacology, PharmacoGenomics Research Center (PGRC), Inje University College of Medicine, Busan, Republic of Korea Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Republic of Korea phshinjg@inje.ac.kr.
authors.forename: Jae-Gook
authors.initials: JG
authors.lastname: Shin
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D004347:Drug Interactions; D006801:Humans; D027361:Organic Anion Transporters / Q000378:metabolism*; D029362:Organic Anion Transporters, Sodium-Independent / Q000378:metabolism
chemical_list: D000995:Antitubercular Agents; D027361:Organic Anion Transporters; D029362:Organic Anion Transporters, Sodium-Independent